Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203369 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
A Phase 1 study, sponsored by Cellectis S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03203369 is a Phase 1 study that was terminated before completion, run by Cellectis S.A.. The registered enrollment target is 1 participants.
The verdict
NCT03203369, a Phase 1 study, was terminated before completion, sponsored by Cellectis S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
Interventions
- BIOLOGICAL UCART123
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03203369
The ClinicalTrials.gov registry entry for NCT03203369 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectis S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UCART123 is the first listed.
NCT03203369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03203369 about?
NCT03203369 is a clinical study titled "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN". A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed...
What is the current status of trial NCT03203369?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-06-28. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03203369?
The interventions under investigation include: UCART123 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03203369?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.